New Developments of Anti-Diabetic Medications in 2013
|
|
- Benedict Walters
- 8 years ago
- Views:
Transcription
1 UMDNJ New Developments of Anti-Diabetic Medications in 2013 Xiangbing Wang, MD., Ph.D. Division of Endocrinology & metabolism Robert Wood Johnson Medical School-UMDNJ (Rutgers), NJ, USA 1
2 Development and Progression of Type 2 Diabetes* (Conceptual Presentation) NGT Insulin IGT/ IFG Type 2 Diabetes Resistance Glucose Postprandial glucose Fasting glucose Relative Activity Insulin level Insulin resistance hepatic and peripheral Beta-cell function Years from Diabetes Diagnosis 2
3 TARGETS FOR HGBA1c individualization ADA/EASD Organization Target (%) ADA <7.0 IDF <6.5 ACE <6.5 EASD <6.5 3
4 4
5 5
6 Pharmacologic Therapy C β-cells Sulfonylureas & meglitinides GKAs and GPR40 α cells glucagon receptor blocker β and α-cells GLP-1 analogs (3) DPP4 inhibitors (4) Liver: Metformin Adrenal gland: GI: a-glucosidase inhibitors colesevelam HCl and Orlistate TZDs: rosiglitazone &Pioglitazone Kidney: SGT-2 inhibitors (New) Brain-Hypothalamus Dopamine receptor agonist 5HT2C receptor blocker Insulin : 6
7 pioglitazone) fibrates) 7
8 TZDs 1. Pioglitazone and rosiglitazone are synthetic ligans for PPAR gamma receptor. TZDs Increase insulin sensitivity with average in reduce A1c 1-1.5% in mono-therapy. 2. Edema, weight gain and fracture are bothersome side effects. 3. CVD safety is the major concern. Rosiglitazone has been removed form Europe and restricted in US. However, new analysis of RECORD, which followed patients for five years did not show a statistically significant difference in heart safety between Rosiglitazone and older diabetes drugs. 4. FDA announced on April 12, 2013 that the agency will hold hearing in June/5-6/2013 to reassess the results of a safety study on rosiglitazone. 5. Pioglitazone s patent expired in 2011 and possible risk of bladder cancer. 6. TZDs become third or fourth line medication, We need more selective TZDs 8
9 Liver-Metformin 1. First line and most commonly used oral agent of treat type 2 DM (ADA/EASD: April, 2012) 2. Reducing hepatic glucose production and increase peripheral glucose uptake. 3. Low A1c 1-1.5%, low incidence of hypoglycemia and no weight gain, in some case weight loss. 4. Caution for pts with Cr mg/dl and elder pt. 5. Most common side effects is GI, lactic acidosis is 3-6/100, Recent data showed benefits effects on CAD protection and cancer mortality. 7. Possible longevity? 9
10 Renal -SGLT-2 inhibitors In type 2 diabetes, renal gluconeogenesis is increased and renal glucose reabsorption might be enhanced because of up-regulation of the SGLT2 transport. SGLT-2 inhibitors reduce fasting and postprandial plasma concentrations of glucose and HbA1c, losing body weight with low risk of hypoglycemia. SGLT-2 inhbitors were associated with increased risk of genital and urinary tract infections in most studies.
11 Renal- SGT-2 inhibitor-dapagliflozen
12 Renal- SGT-2 inhibitor-dapagliflozen FDA recommended against approval of Dapagliflozen, the first of this class of agent in July 2011 (9-6 vote). FDA stalled the drug again on Jan. 6, 2012 for potential risk of bladder and breast cancer. Nine cases of bladder and breast cancer among dapagliflozine group compared with one case each in control group.
13 SGLT-2 Inhibitor - Canagliflozin Canagliflozin Once daily dosing before 1 st meal of day, 100mg or 300mg tablets MOA: Inhibition of SGLT2 reduces reabsorption of glucose in the kidney, resulting in increased urinary glucose excretion, with a consequent lowering of plasma glucose levels as well as weight loss. Blocks approximately grams of glucose per day from being reabsorbed
14 SGLT-2 inhibitor-canagliflozin FDA approved canagliflozin (Invokana) on March 29, First in its class to be approved in the United States. Invokana is expected to generate sales in 2016 of around $468 million, according to analysts' estimates compiled by Thomson Reuters.
15 Effects of SGLT2 inhibitors on clinical measures: Glycemia Endpoints Benefits have been observed for both fasting and postprandial glucose measures, as well as for HbA1c Dapagliflozin (Bristol-Myers Squibb ), refiled for FDA approval Reduction in FBG varied with dose, from 0.8 mmol/l (2.5mg) to mmol/l (10mg) Reductions in BG were achieved when used in combination with other OHA and insulin Reduction in HbA1c 0.6% (2.5mg), and 0.8% - 2.7% (10mg) Canagliflozin (Johnson & Johnson) FDA approval on March 29,2013 Reported to produce reductions in FBG ranging from 0.9 to 2.1mmol/L with daily doses between 50mg and 600mg. The corresponding reduction in HbA1c was 0.9% at a dose of 300mg daily Empagliflozin (Eli Lilly, filed for FDA approval) Significant decreases in FBG when used alone or in combination with metformin, with reductions in blood glucose of 1.7 mmol/l and HbA1c of 0.63% 100mg daily. Significantly greater reductions in HbA1c were achieved in patients with higher starting HbA1c levels
16 Canagliflozin Side Effects cts+-+exact mkwid suzujen2m pcrid
17 GI-Acarbose delays carbohydrate absorption Without acarbose With acarbose Carbohydrate Carbohydrate absorption Carbohydrate absorption Without acarbose With acarbose Duodenum Jejunum Ileum
18 GI-SGLT1/SGLT2 inhibitor 18
19 SGLT1/SGLT2 inhibitor-lx4211 The recently completed study was a four-week, randomized, double-blind, placebocontrolled study in 36 patients with type 2 diabetes. placebo (n=12) or LX4211, 150 mg (n=12) or 300 mg (n=12), once daily for 28 days. There was a marked decrease in fasting plasma glucose in both dose groups, with reductions at week four of 53.4 mg/dl 9150MG) and 65.9 mg/dl (300MG) as compared to 15.1 mg/dl for placebo. (p=0.001 and p<0.001, respectively). Notably, a substantial percentage (42%) of patients in the 300 mg dose group achieved fasting plasma glucose levels of <105 mg/dl at week four of dosing as compared to placebo (p=0.037). Importantly, after only four weeks, HbA1c was significantly reduced by 1.15% in the 150 mg dose group (p=0.036) and by 1.25% in the 300 mg dose group (p=0.017), as compared to 0.49 in the placebo group. patients in both dose groups showed weight reduction, decreased blood pressure and triglycerides relative to placebo. LX4211 demonstrated a favorable safety profile in the study with no dose-limiting toxicities. Adverse events were generally mild and equally distributed across all groups, including the placebo group 19
20 LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial 20
21 GI-other agents for low glucose levels 1. Welchol (colesevelam HCl) is a bile acid sequestrant indicated as an adjunct to diet and exercise to reduce elevated LDL-C and improve glycemic control in adults with T2DM 2. Orlistate blocks pancreatic lipase in the intestine, weight loss and reduction A1c in T2DM 3. Diet or medications change intestinal environments for bacteria? 21
22 22
23 β-cells: Sulfonylureas 1. Insulin secretagogues used in DM >60 years. 2. Reliable means to treat type 2 DM, initial response 50-80%, average in reduce A1c 1% in monotherapy. 3. Relative cheaper. 4. Hypoglycemia and weight gain are bothersome side effects. 5. No effect or less effect in later stage type 2 DM, 6. No effect or less effect in acute hyperglycemia 7. possible more selective or glucose/atp-sensitive sulfonylurea? 23
24 Glucokinase activators increased insulin concentrations and reduced glucose concentrations in animal models of diabetes and patients with type 2 diabetes 24
25 Glucokinase activators (GKAs) Glucokinase activators can additionally reduce glucose concentrations through effects on hepatic glucose metabolism.
26 Possible effects of GKA 26
27 Glucokinase activators (GKAs) GKAs lowered or normalized blood glucose in various animal models of type 2 diabetes. Preliminary clinical activities support their potential More than 100 patents Several compounds are on Phase I & Phase II clinical trials: Piragliatin, AZD6370 (AstraZeneca), TTP-399 (TransTech Pharma, PSN-010 (Astellas/Prosidion/Eli Lilly) and MK0941 (Merck). Projected clinical usage:?
28 Plasma glucose (left panel), serum C-peptide (middle panel), and serum insulin (right panel) concentrations in the postabsorptive state before (predosing) and after administration per os of placebo (orange), piragliatin 25 mg (green), or piragliatin 100 mg This was a phase Ib randomized, double-blind, placebo-controlled crossover trial of two (25 and 100 mg) doses of piragliatin. 2. Patients included 15 volunteer ambulatory patients with mild type 2 diabetes 3. Administration of a single dose of placebo or piragliatin 25 mg or piragliatin 100 mg at 120 Bonadonna R C et al. JCEM 2010;95:
29 29
30 FFAR1; also known as G-protein-coupled receptor 40 [GPR40] 1. AB G protein-coupled receptor 40/free fatty acid receptor 1 (GPR40/FFA(1)) is highly expressed in pancreatic beta cells and mediates free fatty acidinduced insulin secretion. 2. [(3S)-6-({2',6'-dimethyl-4'-[3- (methylsulfonyl)propoxy]biphenyl-3-yl}meth-oxy)- 2,3-dihydro-1-benzofuran-3-yl]acetic acid hemihydrate) (TAK-875), a novel, orally available, selective GPR40 agonist. 3. Molecular Formula: C28H30O7S 30
31 FFAR1 agonist TAK-875 A phase II, randomized, double-blind, placeboand active comparator-controlled trial 426 patients with type 2 diabetes 4,8 and 12 weeks TAK-875 ( mg/day) reducing A1c by roughly 1%, same as glimepiride (2 4 mg/day) with minimum risk of hypoglycaemia. Burant et al. The Lancet 379: , 14 April
32
33
34 TAK-875, Between 33% and 48% of patients reached the ADA target of HbA 1c less than 7% by week 12 at doses of TAK mg and higher, similar to that reported in patients treated with glimepiride. A significant change in HbA 1c compared with placebo was already apparent at week 4 with all doses of TAK-875, suggesting a rapid onset of action, again similar to that seen with glimepiride. By comparison with placebo, the improvement in HbA 1c on TAK-875 is associated with both a reduction in fasting and post-challenge glucose and a decrease in AUC for glucose during OGTT.
35 Currently on phase III study. Long way to go for TAK-875
36 Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease Verified March 28, 2013 by Takeda Global Research & Development Center, Inc 1. A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate Cardiovascular Outcomes of TAK-875, 50 mg in Addition to Standard of Care in Subjects With Type 2 Diabetes and With Cardiovascular Disease or Multiple Risk Factors for Cardiovascular Events 2. MACE composite, including: Cardiovascular death,nonfatal Myocardial infarction, Nonfatal stroke, Hospitalization for unstable angina (with or without revascularization) 3. Estimated Enrollment: 5000 Study Start Date: June 2012 Estimated Study Completion Date: December 2018 Estimated Primary Completion Date: December 2018
37 Brain: Bromocriptine: A novel approach to the treatment of DM2 Diabetes Care 2000, 23:
38 Dopamine and glucose metabolism Bromocriptine is an ergot alkaloid dopamine-d2-receptor agonist that has been available since 1978 to treat patients with prolactinomas and Parkinson s disease and its effects on glycaemic variables have been noted since In a randomised trial of 3095 patients, bromocriptine quick release reduced the risk of CAD compared with placebo (hazard ratio 0 60) by 52 weeks U.S. Food and Drug Administration (FDA) approved its firstin-class drug Cycloset for the treatment of Type 2 diabetes in May After three full years, still very limit usage in USA Bromocriptine is not licensed in Europe/China for treatment of T2DM
39 Brain-hypothalamus-Lorcaserine Lorcaserine is a selective serotonin/5-hydroxytryptamine (5- HT) 2C receptor, with a functional selectivity of about 15 and 100 times that for 5-HT2A and 5-HT2B, respectively FDA approved lorcaserine for weight loss/maintenance on June 29, Lorcaserin has been shown to improve glycemic control in addition to weight loss in T2DM patients (A1c 0.9-1% vs 0.4% ± 0.06% with placebo). Lorcaserin is the first approved drug for treating obesity since the approval of orlistat (Xenical) in The most common adverse events were headache, back pain, nasopharyngitis, and nausea.
40 Drugs targeting α-cell dysfunction GLP-1R agonists and DPP-4 inhibitors reduce glucagon secretion in a glucose-dependent manner. Another mechanism to counter excess glucagon secretion is to block the glucagon receptor or its signaling after binding with the hormone. Animal models with a null mutation of the glucagon receptor or reduced expression with antisense oligonucleotides show significant reduction in basal glycemia and improved glucose tolerance.
41 Diabetes Care. 34 Suppl 2:S236-43,
42
43
44 Other targets: adrenal 11 β-hydroxysteroid dehydrogenase inhibitors INCB13739 Korlym (mifepristone blocks Progesterone and glucocorticoid receptor) was approved by the U.S. FDA to control hyperglycemia in adults with endogenous Cushing s syndrome Feb, 17, This drug was approved for use in patients with endogenous Cushing s syndrome who have type 2 diabetes or glucose intolerance and are not candidates for surgery or who have not responded to prior surgery.
45 Mifepristone blocks Progesterone and glucocorticoid receptor
46 Mifepristone The mean baseline HbA1c of 7.43± 1.52% decreased to 6.29±0.99% at wk 24/ET (P<0.001) The mean reduction in HbA1c was 1.1% (95% CI -1.6, -0.7)
47
48 Liver Biguanides TZDs DPP-4 inhibitors Major Targets of Oral Drug Classes Pancreatic Islet Cells Sulfonylureas Meglitinides DPP-4 inhibitors Glucose level Muscle and Fat TZDs Biguanides DPP-4=dipeptidyl peptidase-4; TZD=thiazolidinediones. 1. DeFronzo RA. Ann Intern Med. 1999;131: Buse JB et al. In: Williams Textbook of Endocrinology. 2003: Gut alpha-glucosidase inhibitors 48
49 谢 谢! THANKS!
50
trends in the treatment of Diabetes type 2 - New classes of antidiabetic drugs. IAIM, 2015; 2(4): 223-
Review Article Pharmacological trends in the treatment of Diabetes type 2 - New classes of antidiabetic Silvia Mihailova 1*, Antoaneta Tsvetkova 1, Anna Todorova 2 1 Assistant Pharmacist, Education and
More informationUpdate on the management of Type 2 Diabetes
Update on the management of Type 2 Diabetes Mona Nasrallah M.D Assistant Professor, Endocrinology American University of Beirut 10 th Annual Family Medicine Conference October 14,2011 Global Prevalence
More informationHarmony Clinical Trial Medical Media Factsheet
Overview Harmony is the global Phase III clinical trial program for Tanzeum (albiglutide), a product developed by GSK for the treatment of type 2 diabetes. The comprehensive program comprised eight individual
More informationCME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus
CME Test for AMDA Clinical Practice Guideline Diabetes Mellitus Part I: 1. Which one of the following statements about type 2 diabetes is not accurate? a. Diabetics are at increased risk of experiencing
More informationCASE A1 Hypoglycemia in an Elderly T2DM Patient with Heart Failure
Hypoglycemia in an Elderly T2DM Patient with Heart Failure 1 I would like to introduce you to Sophie, an elderly patient with long-standing type 2 diabetes, who has a history of heart failure, a common
More informationCardiovascular Effects of Drugs to Treat Diabetes
Cardiovascular Effects of Drugs to Treat Diabetes Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical companies Clinical Trials:
More informationDistinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies)
Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies) Leann Olansky, MD, FACP, FACE Cleveland Clinic Endocrinology Glucose Tolerance Categories FPG Diabetes
More informationGlucose Tolerance Categories. Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies)
Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies) Leann Olansky, MD, FACP, FACE Cleveland Clinic Endocrinology Glucose Tolerance Categories FPG Diabetes
More informationPharmaceutical Management of Diabetes Mellitus
1 Pharmaceutical Management of Diabetes Mellitus Diabetes Mellitus (cont d) Signs and symptoms 2 Elevated fasting blood glucose (higher than 126 mg/dl) or a hemoglobin A1C (A1C) level greater than or equal
More information嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯
The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized
More informationNew and Future Treatments for Diabetes. Mary Charlton Specialty Doctor in Diabetes University Hospital Birmingham BARS Oct 2014
New and Future Treatments for Diabetes Mary Charlton Specialty Doctor in Diabetes University Hospital Birmingham BARS Oct 2014 Conflicts of interest Investigator Carmelina study of Linagliptin (Boehringer
More informationSecond- and Third-Line Approaches for Type 2 Diabetes Workgroup: Topic Brief
Second- and Third-Line Approaches for Type 2 Diabetes Workgroup: Topic Brief March 7, 2016 Session Objective: The objective of this workshop is to assess the value of undertaking comparative effectiveness
More informationVolume 01, No. 08 November 2013
State of New Jersey Department of Human Services Division of Medical Assistance & Health Services New Jersey Drug Utilization Review Board Volume 01, No. 08 November 2013 TO: SUBJECT: PURPOSE: Physicians,
More informationType II diabetes: How to use the new oral medications
Type II diabetes: How to use the new oral medications A TWO-PART INTERVIEW WITH NANCY J.V. BOHANNON, MD, BY DAVID B. JACK, MD Several new oral drugs have been approved for the management of type II diabetes.
More informationComparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians
Clinician Research Summary Diabetes Type 2 Diabetes Comparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians A systematic review of 166 clinical studies published between
More informationNew Treatments for Type 2 Diabetes
New Treatments for Type 2 Diabetes Dr David Hopkins Clinical Director, Division of Ambulatory Care King s College Hospital NHS Foundation Trust Treatments for type 2 diabetes - old & new insulin sulphonylureas
More informationDavid Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010
David Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010 Objectives At the end of the talk, the participants will be able to: 1. Identify the increasing prevalence of type 2 diabetes
More informationTargeting the Kidney. Renal Glucose Transport 11/4/2015. Non insulin Agents Available IBITORS. Chao EC, et al. Nat Rev Drug Discovery. 2010;9:551 559.
SGLT-2i and DPP-IVi in the Management of Diabetes Mellitus Type 2 Abel Alfonso, D.O., F.A.C.E. Endocrinologist November 5, 2015 DIABETES: CURRENT RATES AND PROJECTIONS CDC Press Release 2010: 1 in 3 adults
More informationType 2 Diabetes Medicines: What You Need to Know
Type 2 Diabetes Medicines: What You Need to Know Managing diabetes is complex because many hormones and body processes are at work controlling blood sugar (glucose). Medicines for diabetes include oral
More informationNovel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety
Novel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety Anders Svensson MD, PhD Head of Global Clinical Development Metabolism, F Hoffmann LaRoche Ltd. Basel, Switzerland Overview of
More informationNoninsulin Diabetes Medications Summary Chart Medications marked with an asterisk (*) can cause hypoglycemia MED GROUP DESCRIPTOR
Noninsulin Diabetes Medications Summary Chart Medications marked with an asterisk (*) can cause MED GROUP DESCRIPTOR INSULIN SECRETAGOGUES Sulfonylureas* GLYBURIDE* (Diabeta) (Micronase) MICRONIZED GLYBURIDE*
More informationQuick Reference Guide
2013 Clinical Practice Guidelines Quick Reference Guide (Updated March 2016) 416569-16 guidelines.diabetes.ca diabetes.ca 1-800-BANTING (226-8464) Copyright 2016 Canadian Diabetes Association SCREENING
More informationWelchol (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Takashi Shoda, President and Representative Director (Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
More informationType 2 Diabetes Mellitus and Insulin resistance syndrome in Children
Type 2 Diabetes Mellitus and Insulin resistance syndrome in Children Anil R Kumar MD Pediatric Endocrinology MCV/VCU, Richmond VA Introduction Type 2 diabetes mellitus (T2 DM) has increased in children
More informationType 2 Diabetes. Aims and Objectives. What did you consider? Case Study One: Miss S. Which to choose?!?! Modes of Action
Aims and Objectives This session will outline the increasing complexities of diabetes care, and the factors that differentiate the combinations of therapy, allowing individualisation of diabetes treatment.
More informationThe basal plus strategy. Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE
The basal plus strategy Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE ADA/EASD guidelines recommend use of basal insulin as early as the second step
More informationDM Management in Elderly- What are the glucose targets?
DM Management in Elderly- What are the glucose targets? AFSHAN ZAHEDI, BASC, MD, FRCP(C) ENDOCRINOLOGY WOMEN S COLLEGE HOSPITAL ASSISTANT PROFESSOR OF MEDICINE UNIVERSITY OF TORONTO NOVEMBER 2, 2011 Disclosures
More informationDRUGS FOR GLUCOSE MANAGEMENT AND DIABETES
Page 1 DRUGS FOR GLUCOSE MANAGEMENT AND DIABETES Drugs to know are: Actrapid HM Humulin R, L, U Penmix SUNALI MEHTA The three principal hormones produced by the pancreas are: Insulin: nutrient metabolism:
More informationCASE B1. Newly Diagnosed T2DM in Patient with Prior MI
Newly Diagnosed T2DM in Patient with Prior MI 1 Our case involves a gentleman with acute myocardial infarction who is newly discovered to have type 2 diabetes. 2 One question is whether anti-hyperglycemic
More informationDIABETES MEDICATION-ORAL AGENTS AND OTHER HYPOGLYCEMIC AGENTS
Section Two DIABETES MEDICATION-ORAL AGENTS AND OTHER HYPOGLYCEMIC AGENTS This section will: Describe oral agents (pills) are specific for treating type 2 diabetes. Describe other hypoglycemic agents used
More informationAdd: 2 nd generation sulfonylurea or glinide or Add DPP-4 inhibitor Start or intensify insulin therapy if HbA1c goals not achieved with the above
Guidelines for Type Diabetes - Diagnosis Fasting Plasma Glucose (confirm results if borderline) HbAIC Normal FPG < 00 < 5.5 Impaired Fasting Glucose (IFG) 00 to < 5.7%-.5% Diabetes Mellitus (or random
More informationADJUNCTIVE THERAPIES FOR TYPE 1 DIABETES
ADJUNCTIVE THERAPIES FOR TYPE 1 DIABETES Dr. Mohammad Alhadj Ali, MD, PgDip, MSc, PhD (UK) with Prof. David Owens (UK) Outline Type 1 Diabetes Immunology of Type 1 Diabetes Treatment of Type 1 Diabetes
More informationManagement of Diabetes: A Primary Care Perspective. Presentation Outline
Management of Diabetes: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Presentation Outline
More informationImeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes
Drugs R D (2015) 15:227 232 DOI 10.1007/s40268-015-0099-3 REVIEW ARTICLE Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes Valerie Vuylsteke 1 Lisa M. Chastain 2 Geeta A. Maggu 3 Crystal
More informationDiabetes DIABETES MELLITUS. Types of Diabetes. Classification of Diabetes 6. 10. 2013. Prediabetes: IFG, IGT, Increased A1C
Diabetes Diabetes mellitus is a chronic disease characterized by high levels of blood glucose resulting from defects in insulin production, insulin action, or both. A state of raised blood glucose (hyperglycaemia)
More informationOverview of Diabetes Management. By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health
Overview of Diabetes Management By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health Objectives: Describe the pathophysiology of diabetes. From a multiorgan systems viewpoint. Identify the types of diabetes.
More informationSponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,
More informationEFFIMET 1000 XR Metformin Hydrochloride extended release tablet
BRAND NAME: Effimet XR. THERAPEUTIC CATEGORY: Anti-Diabetic PHARMACOLOGIC CLASS: Biguanides EFFIMET 1000 XR Metformin Hydrochloride extended release tablet COMPOSITION AND PRESENTATION Composition Each
More informationDiabetes and Obesity. The diabesity epidemic
Diabetes and Obesity Frank B. Diamond, Jr. M.D. Professor of Pediatrics University of South Florida College of Medicine The diabesity epidemic Prevalence of diabetes worldwide was over 135 million people
More informationHow To Treat Diabetes
Overview of Diabetes Medications Marie Frazzitta DNP, FNP c, CDE, MBA Senior Director of Disease Management North Shore LIJ Health Systems Normal Glucose Metabolism Insulin is produced by beta cells in
More informationDiabetes Mellitus Type 2
Diabetes Mellitus Type 2 What is it? Diabetes is a common health problem in the U.S. and the world. In diabetes, the body does not use the food it digests well. It is hard for the body to use carbohydrates
More informationClinical Assistant Professor. Clinical Pharmacy Specialist Wesley Family Medicine Residency Program. Objectives
What s New in Diabetes Medications? Matthew Kostoff, PharmD, BCPS, BCACP Clinical Assistant Professor Clinical Pharmacy Specialist Wesley Family Medicine Residency Program Objectives Discuss new literature
More informationMICHIGAN TYPE 2 DIABETES REPORT 2014
MICHIGAN TYPE 2 DIABETES REPORT 2014 CONTENTS Patient Demographics...3 Cases/ALOS/Hospital Charges...4 Professional Charges...5 Use of Services...6 Pharmacotherapy...6 7 Persistency...8 ADA/EASD Position
More informationTYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY. Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU
TYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU Objectives: 1. To discuss epidemiology and presentation
More informationComparative Review of Oral Hypoglycemic Agents in Adults
SECTION 18.5 Comparative Review of Oral Hypoglycemic Agents in Adults Harinder Chahal For WHO Secretariat Table of Contents Acronyms:... 3 I. Background and Rationale for the review:... 4 II. Medications
More informationHow To Get Better Health Care
Kardiovaskulär säkerhet vid behandling av typ 2-diabetes Vad säger senaste data? Michael Alvarsson Kliniken för Endokrinologi, Metabolism och Diabetes Karolinska Universitetssjukhuset Solna Near-normal
More informationStatins and Risk for Diabetes Mellitus. Background
Statins and Risk for Diabetes Mellitus Kevin C. Maki, PhD, FNLA Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL 1 Background In 2012 the US Food and Drug Administration
More informationTake a moment Confer with your neighbour And try to solve the following word picture puzzle slides.
Take a moment Confer with your neighbour And try to solve the following word picture puzzle slides. Example: = Head Over Heels Take a moment Confer with your neighbour And try to solve the following word
More informationType 2 diabetes Definition
Type 2 diabetes Definition Type 2 diabetes is a lifelong (chronic) disease in which there are high levels of sugar (glucose) in the blood. Type 2 diabetes is the most common form of diabetes. Causes Diabetes
More informationTYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.
TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION Robert Dobbins, M.D. Ph.D. Learning Objectives Recognize current trends in the prevalence of type 2 diabetes. Learn differences between type 1 and type
More informationDefinition of Diabetes Mellitus
Definition of Diabetes Mellitus Diabetes mellitus consists of a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action or both. U.S. Diabetes
More informationTreatment Approaches to Diabetes
Treatment Approaches to Diabetes Dr. Sarah Swofford, MD, MSPH & Marilee Bomar, GCNS, CDE Quick Overview Lifestyle Oral meds Injectables not insulin Insulin Summary 1 Lifestyle & DM Getting to the point
More informationAcarbose INITIAL: 25 mg PO TID ($45) Miglitol INITIAL: 25 mg PO TID ($145)
PL Detail-Document #310601 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER June 2015 Drugs for Type 2
More informationACTOS (pioglitazone HCl) in the Management of Type 2 Diabetes PRODUCT INFORMATION GUIDE
MARCH 2008 PRODUCT INFORMATION GUIDE JIM DOWDALLS / PHOTO RESEARCHERS, INC. ACTOS (pioglitazone HCl) in the Management of Type 2 Diabetes PHG0801 SPECIAL ADVERTISING SECTION This Product Information Guide
More informationManagement of Diabetes in the Elderly. Sylvia Shamanna Internal Medicine (R1)
Management of Diabetes in the Elderly Sylvia Shamanna Internal Medicine (R1) Case 74 year old female with frontal temporal lobe dementia admitted for prolonged delirium and frequent falls (usually in the
More informationTreating dual defects in diabetes: Insulin resistance and insulin secretion
Treating dual defects in diabetes: Insulin resistance and insulin secretion Nancy J.V. Bohannon, MD Am J Health-Syst Pharm. 2002; 59(Suppl 9):S9-13 ABSTRACT: The therapeutic goals in patients with type
More informationTreatment of Type 2 Diabetes
Improving Patient Care through Evidence Treatment of Type 2 Diabetes This information is based on a comprehensive review of the evidence for best practices in the treatment of type 2 diabetes and is sponsored
More informationWhen and how to start insulin: strategies for success in type 2 diabetes
1 When and how to start insulin: strategies for success in type diabetes Treatment of type diabetes in 199: with each step treatment gets more complex Bruce H.R. Wolffenbuttel, MD PhD Professor of Endocrinology
More informationCancer treatment and diabetes
Cancer treatment and diabetes Dr Daniel Morganstein Consultant Endocrinologist, 1 2 Diabetes and cancer Cancer and its treatment also poses challenges to managing diabetes Surgery Altered appetite Cachexia
More informationType 2 Diabetes and Prediabetes: A New Understanding of Cause and Treatment. Bruce Latham, M.D. Endocrine Specialists Greenville Health System
Type 2 Diabetes and Prediabetes: A New Understanding of Cause and Treatment Bruce Latham, M.D. Endocrine Specialists Greenville Health System Objectives for this presentation - Understand the thrifty genotype
More informationNew Non-Insulin Therapies for Type 2 Diabetes Mellitus
New Non-Insulin Therapies for Type 2 Diabetes Mellitus Ally P.H. Prebtani Associate Professor of Medicine Internal Medicine, Endocrinology & Metabolism McMaster University Canada Disclosure Relationships
More informationClinical Medicine: Therapeutics. Metformin: A Review of Its Use in the Treatment of Type 2 Diabetes. N. Papanas and E. Maltezos
Clinical Medicine: Therapeutics R e v i e w Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Metformin: A Review of Its Use in the Treatment of Type 2 Diabetes
More informationThere seem to be inconsistencies regarding diabetic management in
Society of Ambulatory Anesthesia (SAMBA) Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Review of the consensus statement and additional
More informationINSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT
INSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT APIRADEE SRIWIJITKAMOL DIVISION OF ENDOCRINOLOGY AND METABOLISM DEPARTMENT OF MEDICINE FACULTY OF MEDICINE SIRIRAJ HOSPITOL QUESTION 1 1. ท านเคยเป นแพทย
More informationMedicines for Type 2 Diabetes A Review of the Research for Adults
Medicines for Type 2 Diabetes A Review of the Research for Adults Is This Information Right for Me? Yes, if: Your doctor or health care provider has told you that you have type 2 diabetes and have high
More informationHow To Help People With Diabetes
Diabetes Medications and Medication Management Christopher Lamer, PharmD, MHS, BCPS, CDE November 2013 Okay, great. Well, I want to say thank you very much for giving me the opportunity to present and
More informationInsulin or GLP1 How to make this choice in Practice. Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust
Insulin or GLP1 How to make this choice in Practice Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust Workshop Over View Considerations/barriers to treatments in type 2
More informationInsulin Therapy In Type 2 DM. Sources of support. Agenda. Michael Fischer, M.D., M.S. The underuse of insulin Insulin definition and types
Insulin Therapy In Type 2 DM Michael Fischer, M.D., M.S. Sources of support NaRCAD is supported by a grant from the Agency for Healthcare Research and Quality My current research projects are funded by
More informationGuidelines for Type 2 Diabetes Diagnosis
Guidelines for Type 2 Diabetes Diagnosis Fasting Plasma Glucose (in asymptomatic individuals, repeat measurement to confirm the test) Normal FPG < 100 2-hr OGTT < 140 HbA1C < 5.5% Impaired Fasting Glucose
More informationGlucagon Receptor Antagonist: LGD-6972 Program Overview and Phase 1b Results
Glucagon Receptor Antagonist: LGD-6972 Program Overview and Phase 1b Results American Diabetes Association s 75th Scientific Sessions June 7, 2015 Boston 2 Safe Harbor Statement The following presentation
More informationBritni Hebert, MD PGY-1
Britni Hebert, MD PGY-1 Importance of Diabetes treatment Types of treatment Comparison of treatment/article Review Summary Example cases 1 out of 13 Americans have diabetes Complications include blindness,
More informationHomeostatic Model Assessment (HOMA)
Homeostatic Model Assessment (HOMA) Historically, insulin resistance (IR) was measured with an invasive test called a euglycemic clamp test. Basically it s a test to measure how much insulin a person needs
More informationType 2 Diabetes. Jonathon M. Firnhaber, MD. Assistant Professor, Residency Program Director East Carolina University Greenville, North Carolina
Type 2 Diabetes Jonathon M. Firnhaber, MD Assistant Professor, Residency Program Director East Carolina University Greenville, North Carolina Verbal Disclosure It is the policy of the AAFP that all individuals
More informationPharmacological Glycaemic Control in Type 2 Diabetes
Pharmacological Glycaemic Control in Type 2 Diabetes Aim(s) and Objective(s) This guideline aims to offer advice on the pharmacological management for those who require measures beyond diet and exercise
More informationAntihyperglycemic Agents Comparison Chart
Parameter Metformin Sulfonylureas Meglitinides Glitazones (TZD s) Mechanism of Action Efficacy (A1c Reduction) Hepatic glucose output Peripheral glucose uptake by enhancing insulin action insulin secretion
More informationCardiovascular Disease Risk Factors Part XII Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner September 15, 2005
Cardiovascular Disease Risk Factors Part XII By James L. Holly, MD Your Life Your Health The Examiner September 15, 2005 As we approach the end of our extended series on cardiovascular disease risk factors,
More informationDiabetes mellitus. Lecture Outline
Diabetes mellitus Lecture Outline I. Diagnosis II. Epidemiology III. Causes of diabetes IV. Health Problems and Diabetes V. Treating Diabetes VI. Physical activity and diabetes 1 Diabetes Disorder characterized
More informationEffective pharmacological treatment regimens for diabetes usually require
Medications Used in Diabetes in Patients Presenting for Anesthesia By Gabrielle O Connor, M.D., M.Sc., CCD, MRCP, FACP Dr. Gabrielle O Connor, a board certified endocrinologist who graduated from University
More informationAnti-Diabetic Agents. Chapter. Charles Ruchalski, PharmD, BCPS. Drug Class: Biguanides. Introduction. Metformin
Chapter Anti-Diabetic Agents 2 Charles Ruchalski, PharmD, BCPS Drug Class: Biguanides The biguanide metformin is the drug of choice as initial therapy for a newly diagnosed patient with type 2 diabetes
More informationSHORT CLINICAL GUIDELINE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SHORT CLINICAL GUIDELINE SCOPE 1 Guideline title Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes 1.1 Short title Type 2
More informationINSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT?
INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT? MARTHA M. BRINSKO, MSN, ANP-BC CHARLOTTE COMMUNITY HEALTH CLINIC CHARLOTTE, NC Diagnosed and undiagnosed diabetes in the United
More informationTreating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background. CAPA 2015 Annual Conference
Treating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group Learning Objectives To accurately make the diagnosis of pre-diabetes/metabolic syndrome To understand the prevalence
More informationPEER REVIEW HISTORY ARTICLE DETAILS
PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf)
More informationMary Bruskewitz APN, MS, RN, BC-ADM Clinical Nurse Specialist Diabetes
Mary Bruskewitz APN, MS, RN, BC-ADM Clinical Nurse Specialist Diabetes Objectives Pathophysiology of Diabetes Acute & Chronic Complications Managing acute emergencies Case examples 11/24/2014 UWHealth
More informationlinagliptin, 5mg film-coated tablet (Trajenta ) SMC No. (746/11) Boehringer Ingelheim / Eli Lilly and Company Ltd
linagliptin, 5mg film-coated tablet (Trajenta ) SMC No. (746/11) Boehringer Ingelheim / Eli Lilly and Company Ltd 09 December 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of
More information25 mg QD-TID @ meals w/1st bite of. food, titrate Q 4 8 weeks; adjust based on 1 postprandial glucose; 100 mg TID max
Table Selected Non-Insulin Antihyperglycemic Agents Class Drug (Brand) Dosing Comments -Glucosidase inhibitors Acarbose a (Precose) 25 mg QD-TID @ meals w/1st bite of MOA: Enzyme inhibitor, delays hydrolysis
More informationSubcutaneous Infusion of GLP-1 for 7 Days Improves Glycemic Control Over a Broad Dose Range in Patients with Type 2 Diabetes
Subcutaneous Infusion of GLP-1 for 7 Days Improves Glycemic Control Over a Broad Dose Range in Patients with Type 2 Diabetes Mario R. Ehlers, 1,2 Roderick E. Harley, 1 Annette L. Mathisen, 1 Roberta Schneider,
More informationEXPLORING THE INTERACTION BETWEEN EXERCISE AND MEDICATION FOR CHRONIC DISEASE: CONSIDERATIONS FOR FITNESS PROFESSIONALS
EXPLORING THE INTERACTION BETWEEN EXERCISE AND MEDICATION FOR CHRONIC DISEASE: CONSIDERATIONS FOR FITNESS PROFESSIONALS Steven T. Johnson, PhD 1 Introduction The prevalence of chronic diseases like cardiovascular
More informationStarting Insulin Sooner Than Later
Starting Insulin Sooner Than Later Rotorua GP Insulin Seminar 13 June 2014 Kingsley Nirmalaraj MBBS, FRACP, FACE Consultant Endocrinologist and Physician Tauranga Hospital/ Bay Endocrinology Ltd Declaration
More informationGuidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center
More informationSweet-taste receptors, glucose absorption and insulin release: Are LCS nutritionally active?
Sweet-taste receptors, glucose absorption and insulin release: Are LCS nutritionally active? Samuel V. Molinary, Ph.D. Consultant, Scientific & Regulatory Affairs ILSI/NA April 6, 2011 Washington, DC Why
More informationNancy S. Swayze. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume V, 2000-2001. A. Background
Efficacy Of Insulin Sensitizing Agents In Subjects With Metabolic Syndrome X And Impaired Glucose Tolerance After 6 Months Of Diet And Exercise Therapy Nancy S. Swayze A. Background Impaired glucose tolerance
More informationPANCREATIC HORMONES, ANTIDIABETIC AGENTS: INSULIN AND ORAL ANTIDIABETICS- handout Iwona Zaporowska-Stachowiak
PANCREATIC HORMONES, ANTIDIABETIC AGENTS: INSULIN AND ORAL ANTIDIABETICS- handout Iwona Zaporowska-Stachowiak The endocrine pancreas (the islets of Langerhans) consists of four types of endocrine cells:
More informationDR. Trinh Thi Kim Hue
TYPE 2 DIABETES IN THE CHILD AND ADOLESCENT DR. Trinh Thi Kim Hue CONTENTS Definition Diagnosis Treatment Comorbidities and Complications Comorbidities and Complications Screening for T2D References DEFINITION
More informationBACKGROUND INTRODUCTORY MEMORANDUM
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Center for Drug Evaluation and Research BACKGROUND INTRODUCTORY MEMORANDUM From: Hylton V. Joffe, M.D., M.M.Sc.
More informationManaging diabetes in the post-guideline world. Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ)
Managing diabetes in the post-guideline world Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ) Overview Pathogenesis of T2DM Aims of treatment The place of glycaemic control Strategies to improve glycaemic
More informationMedicines Used to Treat Type 2 Diabetes
Goodman Diabetes Service Medicines Used to Treat Type 2 Diabetes People who have type 2 diabetes may need to take medicine to help lower their blood glucose, in addition to being active & choosing healthy
More informationUp to Date for Diabetes: Veronica Piziak MD, PhD Professor of Medicine Texas A&M Emeritus Director of Endocrinology Baylor Scott and White
Up to Date for Diabetes: Veronica Piziak MD, PhD Professor of Medicine Texas A&M Emeritus Director of Endocrinology Baylor Scott and White Objectives: What is New in Therapy How to select medications Disclosures:
More informationPANCREATIC HORMONES. Mr. D.Raju, M.pharm, Lecturer
PANCREATIC HORMONES Mr. D.Raju, M.pharm, Lecturer Insulin; Glucagon Diabetes Mellitus 2 types: - Type I; juvenile onset; IDDM - Type II; maturity onset; IIDM Symptomatology: -Early -Late Early manifestations:
More informationMonitoring and Carbohydrate Counting: The Cornerstones of Diabetes Control. Linda Macdonald, M.D. November 19, 2008
Monitoring and Carbohydrate Counting: The Cornerstones of Diabetes Control Linda Macdonald, M.D. November 19, 2008 Objectives Understand the relationship between insulin, carbohydrate intake, and blood
More information